Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-FAP monoclonal antibody F19-I-131 is a radiolabeled murine monoclonal antibody directed against fibroblast activation protein (FAP), a cell-surface glycoprotein that is highly expressed on reactive stromal fibroblasts of epithelial cancers but not present in most normal tissues. It is composed of the monoclonal antibody F19 labeled with the radioactive isotope iodine-131. The antibody specifically targets FAP-positive tumor stromal fibroblasts, which are interposed between tumor capillaries and malignant epithelial cells in more than 95% of primary and metastatic colorectal carcinomas. This selective targeting allows for imaging of colorectal carcinoma lesions as small as 1 cm in diameter. The optimal time for tumor imaging is 3 to 5 days after administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Anti-FAP monoclonal antibody F19-I-131.